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Abstract: In endothelial cells, erythropoietin receptors (EPORs) mediate the protective, 
proliferative and angiogenic effects of EPO and its analogues, which act as EPOR agonists. 
Because hormonal receptors undergo functional changes upon chronic exposure to agonists 
and because erythropoiesis-stimulating agents (ESAs) are used for the long-term treatment 
of anemia, it is critical to determine the mechanism by which EPOR responsiveness is 
regulated at the vascular level after prolonged exposure to ESAs. Here, we investigated 
EPOR desensitization/resensitization in human umbilical vein endothelial cells (HUVECs) 
upon exposure to three ESAs with different pharmacokinetic profiles, epoetin alpha 
(EPOα), darbepoetin alpha (DarbEPO) and continuous EPOR activator (CERA). These 
agonists all induced activation of the transcription factor STAT-5, which is a component of 
the intracellular pathway associated with EPORs. STAT-5 activation occurred with either 
monophasic or biphasic kinetics for EPOα/DarbEPO and CERA, respectively. ESAs, likely 
through activation of the STAT-5 pathway, induced endothelial cell proliferation and 
stimulated angiogenesis in vitro, demonstrating a functional role for epoetins on 
endothelial cells. All epoetins induced EPOR desensitization with more rapid kinetics for 
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CERA compared to EPOα and DarbEPO. However, the recovery of receptor 
responsiveness was strictly dependent on the type of epoetin, the agonist concentration and 
the time of exposure to the agonist. EPOR resensitization occurred with more rapid 
kinetics after exposure to low epoetin concentrations for a short period of desensitization. 
When the highest concentration of agonists was tested, the recovery of receptor 
responsiveness was more rapid with CERA compared to EPOα and was completely absent 
with DarbEPO. Our results demonstrate that these three ESAs regulate EPOR 
resensitization by very different mechanisms and that both the type of molecule and the 
length of EPOR stimulation are factors that are critical for the control of EPOR functioning 
in endothelial cells. The differences observed in receptor resensitization after stimulation 
with the structurally different ESAs are most likely due different control mechanisms of 
receptor turnover at the intracellular level. 
Keywords: endothelial cells; erythropoietin receptor; erythropoiesis-stimulating  
agents; STAT-5 pathway; receptor desensitization; signal resensitization; cell  
proliferation; angiogenesis 
 
Abbreviations: EPO, erythropoietin; EPOR, erythropoietin receptor; DarbEPO, darbepoetin alpha; 
CERA, continuous erythropoietin receptor activator; ESAs, erythropoiesis-stimulating agents; 
HUVEC, human umbilical vein endothelial cells. 
1. Introduction 
Erythropoietin (EPO) is a glycoprotein hormone that is the primary regulator of erythropoiesis [1,2]. 
EPO acts via interaction with a single chain cell surface receptor of the cytokine receptor  
superfamily [3]. The EPO receptor (EPOR) is expressed at high levels on erythroid progenitor cells 
and is the primary target for EPO binding [4]. However, EPORs have also been detected and 
demonstrated to be functionally active on non-hematopoietic cells, including endothelial cells and 
endothelial progenitor cells (EPCs) [5–8]. Therefore, the endothelium is considered a physiological 
target of EPO [9]. EPO is involved in the recruitment and mobilization of endothelial progenitors that 
orchestrate vascular reparative processes and promote endothelial regeneration. In addition, EPO has 
the following important direct effects on mature endothelial cells: (i) stabilizes endothelial structures 
and vascular integrity, such as cell-cell and cell-matrix contacts; (ii) has an important protective action 
under hypoxic conditions by increasing endothelial cell proliferation and protecting cells against 
ischemia and apoptosis caused by inflammatory cytokines [10–14] and (iii) stimulates angiogenesis in 
in vitro and in vivo models, thereby acting as a bona fide direct angiogenic factor [15–20]. These data 
have laid the groundwork for exploring the therapeutic potential of recombinant human EPO and its 
analogous in vascular medicine and their consolidated use in the treatment of anemic states. 
The tissue-protective effects of EPO are mediated by ligand-induced receptor activation and the 
recruitment of specific intracellular signaling pathways, including the JAK2/STAT-5 and PI3K/Akt 
protein kinases [21–24]. The first signaling molecule that binds to ligand-activated receptors and 
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induces an intracellular signaling cascade is the JAK2 tyrosine kinase, a cytoplasmic tyrosine kinase 
that phosphorylates tyrosine residues within the EPOR itself. EPOR phosphorylation provides docking 
sites for a variety of signaling molecules, such as STAT-5, PI3K and MAPK. These activated kinases 
translocate to the nucleus and induce the transcription of target genes that are involved in both the 
inhibition of apoptosis and cell proliferation. STAT-5 has also been described as the major 
transcription factor that is involved in EPO-mediated proliferative and angiogenic effects on 
endothelial cells [15,24,25]. In addition, the beta-common receptor, which is a shared receptor subunit 
for the interleukin-3, interleukin-5 and GM-CSF receptors, has been demonstrated to mediate several 
non-hematopoietic effects of EPO in endothelial cells, such as eNOS activation and angiogenesis [26]. 
All known erythropoietin-stimulating agents act as EPOR agonists [27,28], and their clinical 
efficacy is highly dependent on the functional responsiveness of surface membrane receptors, which 
are known to be modulated in both physiological and pathological conditions by specific and complex 
regulatory mechanisms.  
Some of these mechanisms regulate receptor abundance and/or availability, whereas others may 
alter the responsiveness of downstream signaling molecules to receptor engagement. These alterations 
in receptor responsiveness include receptor desensitization, downregulation and resensitization. These 
mechanisms are critical for the regulation of temporal and spatial aspects of receptor signaling and 
serve to ensure that extracellular stimuli are translated into intracellular signals of the appropriate 
magnitude, duration and specificity.  
Negative regulatory pathways that lead to the termination of intracellular signals are simultaneously 
turned on by EPO itself. These negative signaling events include receptor de-phosphorylation by  
the phosphotyrosine-phosphatase SHP1 [29], internalization and degradation of the activated  
receptor [30–34] and receptor downregulation induced by lysosomes and the proteasome [35–37]. 
Therefore, studying receptor activation following treatment with drugs represents an important 
approach to identify novel therapeutic strategies and clarify the differences between structurally related 
drugs at the molecular level. 
In this study, we investigated the effects of different epoetin derivatives, epoetin alpha (EPOα), 
darbepoetin (DarbEPO) and continuous EPOR activator (CERA), on EPOR desensitization and 
signaling resensitization. We also specifically evaluated EPOR-mediated activation of intracellular 
STAT-5 in HUVECs. In addition, we determined the effects of EPO derivatives on HUVEC 
angiogenesis and viability and involvement of the STAT-5 pathway in these functional effects. These 
results could elucidate the different signaling pathways that are activated by EPO derivatives at the 
molecular level and may also provide information regarding the therapeutic potential of these drugs in 
endothelial repair and regeneration. 
2. Results 
2.1. Optimization of Experimental Conditions  
EPOα-induced STAT-5 phosphorylation (1 IU/mL for 5, 10 and 30 min) was evaluated by 
maintaining HUVECs under three different culture conditions, as reported in the Materials and 
Methods section, and 25 ng/mL VEGF was used as a positive control. The results showed that  
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1 IU/mL EPOα stimulated STAT-5 phosphorylation in a time-dependent manner in HUVECs 
maintained in M199 medium devoid of FBS and growth factors and supplemented with 0.5% BSA and 
0.2 mM OVD for 24 h before the experiment (Figure 1). These results suggest that the addition of 
BSA, which has trophic effects, and OVD, which reduces protein de-phosphorylation, produces the 
ideal experimental conditions to assess EPOR responsiveness to EPOα. The same results were 
obtained by treating cells with VEGF. Based on these results, these experimental conditions were used 
for all subsequent experiments. 
Figure 1. Vascular endothelial growth factor (VEGF)- and epoetin alpha (EPOα)-mediated 
STAT-5 phosphorylation. Human umbilical vein endothelial cells (HUVECs) were treated 
with 25 ng/mL VEGF (10 min) or 1 IU/mL EPOα (5–10 and 30 min) under three different 
cell culture conditions. White bar: replacement of cell culture medium for 24 h with M199 
without fetal bovine serum (FBS) and growth factors supplemented with 0.5% bovine 
serum albumin (BSA) and 0.2 mM orthovanadate. Gray bars: replacement of cell culture 
medium for 24 h with M199 without FBS and growth factors. Black bars: replacement of 
cell culture medium for 12 h with M199 medium without FBS and growth factors 
supplemented with 0.2 mM orthovanadate 30 min before the experiments. In each 
experimental condition, cell responsiveness was evaluated by assessing whether VEGF or 
EPOα stimulated STAT-5 phosphorylation. The data are expressed as the percent STAT-5 
phosphorylation compared to the untreated control cells (set to 100%) and represent the 
mean ± SEM of three different experiments. *** p < 0.001; ** p < 0.01 vs. basal value. 
 
2.2. EPOα-, DarbEPO- and CERA-Mediated STAT-5 Phosphorylation:  
Concentration- and Time-Dependence 
HUVECs were pre-incubated for 24 h in M199 medium supplemented with 0.5% BSA and  
0.2 mM OVD. The cells were then treated for five minutes with various concentrations of EPOα, 
DarbEPO or CERA (0.5 to 10 IU/mL). A control sample was used for each experimental condition to 
obtain the basal value (Figure 2). The results demonstrate that all tested epoetins stimulated STAT-5 
phosphorylation in a concentration-dependent manner with a maximal effect at 1 IU/mL for EPOα and 
DarbEPO and 5 IU/mL for CERA. No significant differences between the EPOα and DarbEPO  
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dose-response curves were detected, whereas at the highest concentration of CERA, higher maximal 
STAT-5 phosphorylation was induced (Figure 2).  
Figure 2. Concentration-dependence of EPOα-, darbepoetin alpha (DarbEPO)- and 
continuous erythropoietin receptors activator (CERA)-mediated STAT-5 phosphorylation. 
HUVECs were treated with different epoetin concentrations (0.5–10 IU/mL) for 5 min. 
STAT-5 phosphorylation levels were quantified using an enzyme-linked immunosorbent 
assay (ELISA) kit (see Materials and Methods). The data are expressed as the percent 
STAT-5 phosphorylation compared to the untreated control cells (set to 100%) and 
represent the mean ± SEM of three different experiments. 
 
The time-course of EPOα- and DarbEPO-mediated STAT-5 phosphorylation was also evaluated. 
After 24 h in the appropriate culture medium, HUVECs were treated with the epoetins at the 
concentration causing the maximal effect (1 IU/mL for EPOα and DarbEPO; 5 IU/mL for CERA) for 
1, 5, 10 and 30 min. A control sample was used for each experimental condition to obtain the basal 
value (Figure 3A). The results demonstrate that 1 IU/mL EPOα and 1 IU/mL DarbEPO stimulated 
STAT-5 phosphorylation in a similar, time-dependent manner with rapid and transient kinetics and a 
maximal effect after treatment for 5 min. Cell treatment with CERA induced a biphasic activation of 
STAT-5 with two peaks at 5 and 30 min (Figure 3A). To investigate STAT-5 activation kinetics in 
detail, similar experiments were performed using 25 ng/mL VEGF and 10 IU/mL GM-CSF as positive 
controls (Figure 3B). The data confirmed that VEGF induces time-dependent activation of STAT-5 
with a maximal effect after 30 min. GM-CSF showed a biphasic effect similar to CERA. These results 
suggest that the kinetics of STAT-5 activation follow different time-courses depending on the type of 
epoetin used to induce activation.  
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Figure 3. Time-dependence of EPOα-, DarbEPO- and CERA-mediated STAT-5 
phosphorylation. HUVECs were treated with medium alone (control) or 1 IU/mL EPOα,  
1 IU/mL DarbEPO or 5 IU/mL CERA for different periods of time ranging from 5  
to 30 min (A). Aliquots of cells were treated with VEGF (25 ng/mL) or  
granulocyte-macrophage colony-stimulating factor (GM-CSF) (10 IU/mL) for the same 
time intervals as above (B). STAT-5 phosphorylation levels were quantified using an 
ELISA kit (see Materials and Methods). The data are expressed as the percent STAT-5 
phosphorylation compared to the untreated control cells (set to 100%) and represent the 
mean ± SEM of three different experiments. 
 
Figure 4. Effect of the STAT-5 inhibitor on EPOα-, DarbEPO- and CERA-mediated 
STAT-5 phosphorylation. HUVECs were treated with medium alone (basal) or 1 IU/mL 
EPOα, 1 IU/mL DarbEPO or 5 IU/mL CERA for 5–30 min or VEGF for 10 min in the 
absence (gray bar) or presence of the STAT-5 inhibitor (80 µM, black bar). STAT-5 
phosphorylation levels were quantified using an ELISA kit (see Materials and Methods). 
The data are expressed as the per cent STAT-5 phosphorylation compared to the untreated 
control cells (set to 100%) and represent the mean ± SEM of three different experiments. 
*** p < 0.001; ** p < 0.01: * p < 0.05 vs. basal value. ### p < 0.001; ## p < 0.01 vs. 
control (in the absence of inhibitor). 
 
To verify the specificity of the results, the same experiments evaluating the effects of VEGF and 
the different ESAs on STAT-5 phosphorylation were performed in the presence of a STAT-5 inhibitor 
N'-((4-Oxo-4H-chromen-3-yl)methylene)nicotinohydrazide. This compound is a cell permeable  
non-peptidic nicotinoyl hydrazone that selectively targets the SH2 domain of STAT-5 (IC50 = 47 µM) 
and has a much less potent effect towards the SH2 domain of STAT-1, STAT-3 or Lck  
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(IC50 > 500 µM) [38]. The results depicted in Figure 4 show that the STAT-5 inhibitor completely 
prevented VEGF- and ESA-mediated activation of STAT-5 phosphorylation, demonstrating that 
VEGF- and ESA-mediated activation of STAT-5 phosphorylation is a specific effect. 
2.3. Effect of EPOα, DarbEPO and CERA on HUVEC Viability  
To verify the role of the different ESAs in endothelial cell viability, an MTS assay was used to 
analyze metabolically active cells after treatment with the different ESA derivatives in the absence or 
presence of the STAT-5 inhibitor. As shown in Figure 5, EPOα and DarbEPO induced a significant 
increase in cell viability compared to the untreated control cells (EPOα: 121.7% ± 0.9%, p < 0.01; 
DarbEPO: 113.4% ± 1.1%, p < 0.05 vs. basal value set to 100%). These effects appeared to be 
completely prevented following incubation of the cells with the STAT-5 inhibitor, suggesting that the 
STAT-5 pathway is primarily involved in the EPOα- and DarbEPO-mediated effects on cell viability. 
By contrast, 5 IU/mL CERA treatment for 72 h had no significant effect on cell viability. 
Figure 5. Effect of erythropoiesis-stimulating agents (ESAs) on HUVEC viability. The 
cells were treated for 72 h with EPOα (1 IU/mL), DarbEPO (1 IU/mL) or CERA  
(5 IU/mL) in the absence or presence of 80 µM STAT-5 inhibitor. Cell viability was 
determined by an MTS assay, as described in the Methods section. The data are expressed 
as the percent cell viability compared to the untreated basal cells (set to 100%) and represent 
the mean ± SEM of three different experiments. ** p < 0.01; * p < 0.05 vs. basal value. 
 
2.4. EPOα-, DarbEPO- and CERA-Mediated Angiogenesis of HUVECs In Vitro 
To determine whether ESA derivatives could affect the angiogenic property of endothelial cells, we 
performed a capillary-like tube formation assay on Matrigel. This is a commonly used method for the 
evaluation of in vitro angiogenesis. HUVECs were pre-treated for 24 h with 1 IU/mL EPOα, 1 IU/mL 
DarbEPO or 5 IU/mL CERA in the absence or presence of 80 µM STAT-5 inhibitor. The cells were 
then seeded onto Matrigel in 24-well plates with fresh medium. The capillary-like tube formation 
assay was developed, and photos were taken after a 20 h incubation (Figure 6A). Quantitative analysis 
revealed that the number of mesh-like structures following treatment with the three ESAs was 
significantly higher compared to the untreated control (Figure 6B, EPOα 148.4 ± 26.8, p < 0.05; 
DarbEPO 163.1 ± 35.3, p < 0.01; CERA 170.8 ± 26.3, p < 0.001 vs. basal value). These data suggest 
that EPOα, DarbEPO and CERA promoted the angiogenesis of HUVECs in vitro. However, the 
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STAT-5 inhibitor alone induced a significant inhibitory effect on capillary tube formation (data not 
shown) and was, therefore, not suitable under our experimental conditions to verify the involvement of 
STAT-5 in ESA-mediated pro-angiogenic activity. 
Figure 6. Effect of ESAs on HUVEC angiogenesis. The cells were treated with medium 
alone (basal) or ESAs (1 IU/mL EPOα, 1 IU/mL DarbEPO or 5 IU/mL CERA) for 24 h 
before seeding onto Matrigel with fresh medium. Capillary-like tube formation was 
observed by microscopy and quantified using the ImageJ program. (A) Representative 
pictures of HUVEC tubule formation on Matrigel after 24 h drug incubation. (a) Basal;  
(b) STAT-5 inhibitor; (c) 1 IU/mL EPOα; (d) 1 IU/mL DarbEPO; (e) 5 IU/mL CERA 
(original magnification = 10×). (B) The number of mesh-like structures were quantified 
and expressed as a percent of the control sample. The data are expressed as the  
mean ± SEM of three independent experiments performed in duplicate. *** p < 0.001;  
** p < 0.01; * p < 0.05 vs. basal value. 
 
 
2.5. EPOR Desensitization 
The susceptibility of EPOR to desensitization upon prolonged agonist exposure and the  
time-dependence of this phenomenon were evaluated by incubating HUVECs with 1 IU/mL EPOα,  
1 IU/mL DarbEPO or 5 IU/mL CERA for graded time intervals ranging from 5 to 120 min  
(Figure 7A). The results demonstrate that EPOα (1 IU/mL) treatment induced time-dependent receptor 
desensitization with a maximal effect after 60 min and a t1/2 value of 18.17 min. Similarly, DarbEPO  
(1 IU/mL) treatment desensitized EPORs with a t1/2 value of 11.21 min. Statistical analysis showed no 
significant differences in the desensitization kinetics of these two epoetins. By contrast, CERA 
induced EPOR desensitization with more rapid kinetics compared to the other epoetins  
(t1/2 = 2.77 min). 
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Figure 7. EPOR desensitization. (A) Time-dependence: cells were pre-treated with 
medium alone (control) or 1 IU/mL EPOα, 1 IU/mL DarbEPO or 5 IU/mL CERA for 
different periods of time ranging from 5 to 120 min. (B) Concentration-dependence: cells 
were pre-treated with medium alone (control) or different EPOα, DarbEPO or CERA 
concentrations (0.5–10 IU/mL) for 60 min. The cells were then washed and stimulated by 
the addition of 1 IU/mL EPOα, 1 IU/mL DarbEPO or 5 IU/mL CERA for 5 min. STAT-5 
phosphorylation levels were quantified using an ELISA kit (see Materials and Methods). 
The data are expressed as the percent STAT-5 phosphorylation compared to the untreated 
control cells (set to 100%) and represent the mean ± SEM of three different experiments. 
 
 
The data from the different experiments were normalized by concurrently performing an 
immunoenzymatic assay to quantify the total amount of STAT-5 protein. The results indicate that the 
various cell treatments did not alter the total protein levels of STAT-5 (data not shown). 
In a similar set of experiments, the concentration-dependence of EPOR desensitization was 
assessed by exposing the HUVECs to different concentrations of EPOα, DarbEPO or CERA (0.5 to  
10 IU/mL) for a fixed period of time (60 min) (Figure 7B). The results demonstrate that the three 
epoetins induced EPO receptor desensitization in a concentration-dependent manner. EPOα and 
DarbEPO desensitization appeared maximal at 1 IU/mL and tended to decrease at higher ligand 
concentrations, whereas CERA induced a concentration-dependent effect at all tested concentrations. 
These results suggest that CERA regulates EPOR signaling differently than EPOα and DarbEPO. 
2.6. EPOR Resensitization 
The resensitization of desensitized EPOR was then investigated following the induction of receptor 
desensitization with EPOα, DarbEPO or CERA at different concentrations for different exposure times 
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(18 or 54 min). In the first set of experiments, HUVECs were pre-incubated with 1 IU/mL EPOα or 
DarbEPO for 18 or 54 min to induce receptor desensitization. In the second set of experiments, 
HUVECs were desensitized for the same period of time by pre-treating the cells with 3 IU/mL EPOα, 
3 IU/mL DarbEPO or 5 IU/mL CERA. Following desensitization, the cells were washed to remove the 
ligands and placed in agonist-free medium for various times to allow for receptor resensitization 
(wash-out). EPOR responsiveness in the control untreated cells, in the desensitized cells and following 
resensitization was then evaluated by assessing EPOα- (1 IU/mL for 5 min) DarbEPO- (3 IU/mL for  
5 min) or CERA-mediated (5 IU/mL for 5 min) phosphorylation of STAT-5.  
As expected, following treatment with 1 IU/mL EPO, receptor desensitization occurred in a  
time-dependent manner (Figure 8A). Recovery of receptor responsiveness was evaluated following 
cell wash-out for 2–24 h. As depicted in Figure 5A, when EPOR was desensitized for 18 min with 
EPOα (1 IU/mL), receptor resensitization began after a 2 h wash-out period and was complete after  
24 h. When receptor desensitization was induced for 54 min with EPOα (1 IU/mL), receptor 
resensitization was detected only after a 24 h wash-out period. As expected, these results suggest that 
the kinetics of receptor resensitization depend on the duration of receptor exposure to the agonist and 
is slower when receptor desensitization is induced by a longer exposure to the agonist. 
Figure 8. EPOR resensitization following 1 IU/mL EPOα- or DarbEPO-induced receptor 
desensitization. HUVECs were pre-treated with medium alone (control) or 1 IU/mL EPOα 
(A) or 1 IU/mL DarbEPO (B) for 18 or 54 min to induce receptor desensitization. Then, 
cells were the washed and replaced in medium alone for different periods of time (2 to  
24 h) to allow for receptor resensitization. All samples were then stimulated by the addition 
of 1 IU/mL EPOα or 1 IU/mL DarbEPO for 5 min and STAT-5 phosphorylation levels 
were quantified. The data are expressed as the percent STAT-5 phosphorylation compared 
to the untreated control cells (set to 100%) and represent the mean ± SEM of three 
different experiments. ** p < 0.01; * p < 0.05 vs. DES'. 
 
Concurrently, we evaluated EPOR resensitization following induction of desensitization with 
DarbEPO at the same concentrations. As shown in Figure 8B, following treatment of the HUVECs 
with DarbEPO (1 IU/ml) for 18 min, receptor responsiveness was restored only after a 6 hour wash-out 
period. Moreover, when the cells were treated with DarbEPO for 54 min, receptor responsiveness 
remained absent after a 24 h wash-out period, demonstrating that for this DarbEPO exposure time, 
receptor resensitization does not occur within the time period evaluated in this study. It is also evident 
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that EPOR resensitization kinetics depend on the type of agonist used in the pre-exposure phase. 
During the desensitization period, receptor responsiveness recovery was more rapid with EPOα 
compared to DarbEPO. 
These experiments were also performed using higher agonist concentrations. As depicted in  
Figure 9A, when receptor desensitization was induced with the higher concentration of EPOα  
(3 IU/mL), the resensitization kinetics were slower with significant recovery only after a 24 h wash-out 
period. Under these conditions, no significant differences were observed following either the 18 or  
54 min desensitization. When receptor desensitization was induced with DarbEPO (3 IU/mL), the 
receptor remained desensitized after the 24 h cell wash-out period without any recovery of 
responsiveness (Figure 9B). 
Figure 9. EPOR resensitization following 3 IU/mL EPOα-, 3 IU/mL DarbEPO- or  
5 IU/mL CERA-induced receptor desensitization. HUVECs were pre-treated with medium 
alone (control) or 3 IU/mL EPOα (A), 3 IU/mL DarbEPO (B) or 5 IU/mL CERA (C) for 
18 or 54 min to induce receptor desensitization. The cells were then washed and replaced 
in medium alone for different periods of time (2 to 24 h) to allow for receptor 
resensitization. All samples were then stimulated by the addition of 3 IU/mL EPOα,  
3 IU/mL DarbEPO or 5 IU/mL CERA for 5 min, and STAT-5 phosphorylation levels were 
quantified. The data are expressed as the percent STAT-5 phosphorylation compared  
to the untreated control cells (set to 100%) and represent the mean ± SEM of three  
different experiments. ** p < 0.01; * p < 0.05 vs. DES'. 
 
The same experiments were performed following induction of EPOR desensitization with 5 IU/mL 
CERA. As shown in Figure 9C, following treatment with CERA (5 IU/mL) for 18 min, receptor 
responsiveness was restored after a 2 h wash-out period. By contrast, when the HUVECs were treated 
with CERA for 54 min, receptor responsiveness was recovered only after a 18–24 h wash-out period. 
This finding demonstrates that with CERA, the resensitization kinetics also depend on the duration of 
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agonist exposure. By comparing the kinetics of EPOR resensitization obtained with the three epoetins, 
it is evident that CERA, when used at higher concentrations, allows for faster recovery of receptor 
responsiveness compared to EPOα and DarbEPO. 
Overall, these results demonstrate that EPOR resensitization kinetics depend on the type of 
epoietin, its concentration and the length of time for desensitization. For both EPOα and DarbEPO, the 
resensitization kinetics are faster at lower concentrations and shorter exposure times. For CERA, the 
resensitization kinetics are quite rapid at high agonist concentrations. Our data also suggest that the 
regulation of EPOR desensitization/recycling by these three different epoetins is significantly different 
at the molecular level. 
2.7. Effects of ESAs on EPOR Expression Levels  
To evaluate whether there are any changes in EPOR at the mRNA and protein levels during EPOR 
desensitization/resensitization, real-time PCR and immunoblotting  studies were performed. 
Using RT-PCR, we demonstrated that treatment of HUVECs with EPOα, DarbEPO or CERA for 
54 min, which allowed for complete receptor desensitization, induced a significant reduction in EPOR 
mRNA expression without any significant difference among the three EPO derivatives. When the cells 
were resensitized in the absence of agonists for 24 h, a marked difference in epoetin-mediated 
regulation of EPOR mRNA was observed. When the cells were desensitized with EPOα or CERA and 
then subjected to resensitization, EPOR mRNA levels returned to basal levels. By contrast, after 
receptor desensitization with DarbEPO and subsequent cell resensitization, EPOR mRNA levels remained 
low (Figure 10). These data suggest that epoetins control transcription of EPOR by different mechanisms at 
the nuclear level. Furthermore, these differences may correlate with the differences observed in EPOR 
recycling on the plasma membrane after receptor activation by the three EPO derivatives. 
Figure 10. Effect of EPOR desensitization/resensitization on EPOR mRNA expression 
levels. The cells were pre-treated with medium alone (control) or 1 IU/mL EPOα, 1 IU/mL 
DarbEPO or 5 IU/mL CERA for 54 min and then washed-out for 24 h. RT-PCR for the 
EPOR gene was performed, and β-actin used as the house-keeping gene. The data are 
expressed as the fold mRNA EPOR changes vs. control. * p < 0.05, ** p < 0.01 vs. control cells. 
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3. Discussion  
Until recently, EPO has primarily been regarded as the hematopoietic cytokine required for the 
survival, proliferation and differentiation of committed erythroid progenitor cells [1,4]. Treatment with 
EPO and its analogous has, therefore, represented a major breakthrough in the therapy of anemic 
states. However, EPO shows pleiotropic and regenerative properties in various other tissues, including 
the endothelium and is also becoming relevant to cardiovascular medicine [9]. 
Much conflicting information has been reported regarding the benefit/risk ratio resulting from the 
action of EPO on endothelial cells. Several groups have demonstrated that long-term therapy with EPO 
may induce increases in markers of endothelial injury and may favor platelet aggregation in 
hemodialyzed patients by shifting the balance of the haemostatic system towards thrombosis [39–42]. 
Theoretically, an increased hematocrit level could contribute to elevated blood pressure and/or 
vascular thrombosis. By contrast, recent data have demonstrated that EPO therapy does not affect 
coagulation activation [43]. High levels of EPO can reduce ischemia-reperfusion injury in the heart 
through an immediate response involving EPO-stimulation of nitric oxide production by  
endothelium [7] and a long-term effect involving the mobilization of endothelial progenitor cells from 
the bone-marrow and subsequent regeneration of the endothelium [7,10]. In addition, it has been 
demonstrated that low doses of ESAs, including DarbEPO and carbamylated derivative (CEPO), are 
cytoprotective and may have utility in preventing ischemia-related progressive vascular injury and 
organ failure [44]. Specifically, an optimal dose of DarbEPO has been suggested for the treatment of 
myocardial ischemia/reperfusion models in mice (3.0 μg/Kg [45]) and rats (2.5 μg /Kg [46]). Different 
authors have reported that low-dose, but not high-dose, EPO administration improves myocardial 
infarction in patients with STEMI [47,48]. The potential adverse effects of EPO at high doses included 
vascular access thrombosis and other thrombotic complications. Furthermore, high doses of ESAs have 
been associated with elevated levels of inflammatory biomarkers that may contribute to the excess risk 
associated with high-dose ESA [49]. The selection of ESA doses that have protective effects with the 
understanding that “high is bad, low is good” may emerge from these clinical trials. 
The balance between the benefits and risks in the use of epoetins most likely depends on several 
factors, including the effective drug dose, the duration of drug treatment, drug pharmacokinetics and 
the functional responsiveness of endothelial EPORs over time. These parameters could account for the 
differences in therapeutic effectiveness and side effects demonstrated for the different ESAs. 
In this study, we demonstrate for the first time that three structurally different EPOR agonists, 
DarbEPO, EPOα and CERA, regulate the functional response of EPORs over time in different ways. 
In particular, we show that EPOα, DarbEPO and CERA, three clinically used ESAs, desensitize 
EPORs and display marked differences in EPOR resensitization kinetics, which is a critical process for 
restoring the functional response of the receptor at the membrane following prolonged agonist 
exposure and desensitization.  
EPOR desensitization and resensitization were evaluated by assessing the intracellular STAT-5 
phosphorylation/activation state. This phosphorylation pathway has been identified as one of the most 
important intracellular signaling pathways involved in EPOR-mediated effects in different cell  
types [21–24]. EPO-dependent tyrosine phosphorylation, nuclear translocation and activation of DNA 
binding of STAT-5 have been clearly demonstrated [50]. 
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As a first step, we assessed whether and the mechanism by which EPOα, DarbEPO and CERA 
activate EPOR signaling in HUVECs. All agonists activated STAT-5 phosphorylation in a 
concentration-dependent manner with different kinetics. Both EPOα and DarbEPO showed a 
monophasic activation of STAT-5 phosphorylation peaking at a concentration of 1 IU/mL. CERA 
induced a more marked activation of STAT-5 with different, biphasic kinetics and a maximum at  
5 IU/mL. These results suggest a different mechanism of action for DarbEPO and CERA at the 
receptor level. We hypothesize that CERA induces the recruitment of additional EPORs to the plasma 
membrane, thereby triggering the amplification of receptor signaling followed by a biphasic response.  
To evaluate whether activation of the STAT-5 pathway induced by ESAs could have a functional 
role in endothelial cells, viability and angiogenesis assays were performed. We demonstrated that 
EPOα induced a significant increase in cell viability through a mechanism involving STAT-5 
activation, which has yet to be demonstrated in other cell lines, such as trophoblasts [51] and 
endothelial cells [15]. Similar effects were obtained with DarbEPO, whereas CERA did not induce any 
significant change in cell viability. The inability of CERA to modulate cell viability after a long period 
of incubation with the HUVECs (72 h) could be caused by a distinct molecular mechanism of 
interaction of this derivative at the receptor level with respect to classical agents (see below) and the 
differential regulation of intracellular survival pathways.  
Using the Matrigel in vitro angiogenesis assay model, we then investigated whether the different 
ESAs may directly affect vascular network formation. HUVEC incubation with EPOα, DarbEPO or 
CERA induced a significant increase in the cell number of mesh-like structures, a valid topological 
parameter of angiogenesis [52,53], suggesting that these compounds have pro-angiogenic effects on 
endothelial cells. However, because the STAT-5 inhibitor alone showed an inhibitory effect on 
endothelial cell remodeling (data not shown), it was not possible to demonstrate the involvement of 
this pathway in ESA-mediated angiogenic effects, although it has been reported that EPO is a  
pro-angiogenic factor in HUVECs and that the phosphorylation and nuclear translocation of STAT-5 is 
important for the effects of EPO on endothelial cells [15]. 
These data suggest that STAT-5 activation represents a good functional marker to investigate the 
regulatory mechanisms of EPOR in response to ESAs in endothelial cells. 
Therefore, we investigated whether and the mechanism by which prolonged exposure of cells to 
EPOα, DarbEPO and CERA induces EPOR desensitization. For the first time, we demonstrated that 
incubation of HUVECs with these agonists for graded period of times induces significant receptor 
desensitization as evaluated by impairment of the receptor-mediated response. No significant 
differences in the desensitization kinetics induced by EPOα and DarbEPO were observed, suggesting 
that these two agonists act by similar mechanisms. By contrast, CERA caused a more rapid EPOR 
desensitization compared to the other ESAs. These differences could be explained by assuming that 
the different ESA derivatives act by distinct molecular mechanisms at the receptor level. Compared to 
EPOα, CERA has a lower affinity for its receptor and dissociates more quickly [54]. The lower 
receptor affinity could justify the need for a higher CERA concentration to obtain the maximal 
activation of intracellular signaling. Furthermore, the rapid association/dissociation kinetics of CERA 
could be the basis for the rapid EPOR-induced desensitization.  
Finally, we assessed whether and the mechanism by which agonist removal after EPOR 
desensitization could restore receptor function. Among the regulatory mechanisms controlling the 
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functionality of plasma membrane receptors, resensitization is a key event in ensuring the recovery of 
membrane receptors to an active state and allowing these receptors to respond to subsequent stimuli.  
Different resensitization kinetics were observed after exposure to EPOα and DarbEPO for different 
times. When receptor desensitization was induced for a shorter period of time (18 min), receptor 
responsiveness recovery was observed after a 2 h wash-out period. By contrast, when receptor 
desensitization was induced for a longer period of time (54 min), receptor resensitization was detected 
only after a 24 h wash-out period. As expected from studies on other membrane receptors, these results 
demonstrate that the exposure-time and, to a lesser extent, the concentration of the agonist, are crucial 
factors that regulate the time needed for resensitization. When DarbEPO was used in the 
desensitization/resensitization experiments, the recovery of functional responsiveness occurred with 
significantly slower kinetics. At low DarbEPO doses and following short desensitization times, 
significant EPOR resensitization occurred only after a 6 h cell wash-out period. By increasing the 
DarbEPO concentration to 3 IU/mL and/or the desensitization period to 54 min, EPOR responsiveness 
appeared to be completely absent even after a 24 h wash-out period. When CERA was used in the 
desensitization experiments, the recovery of receptor responsiveness at the same desensitization times 
was faster for CERA compared to EPOα. Taken together, these results suggest that EPOα, DarbEPO 
and CERA differentially affect the intracellular machinery involved in the recycling of EPORs to the 
plasma membrane. It is likely that structural differences in the molecules may affect intracellular 
trafficking of the receptors and may change the permanence of the activated receptors at the cell 
surface. EPOR ubiquitination and internalization is a critical event controlling the amplitude and 
duration of EPO signaling [55], because the cell surface level of EPOR controls cellular EPO 
sensitivity [56] and endocytosis may lead to destruction of the activated protein complex to terminate 
signaling [57]. Furthermore, receptor internalization is a pre-requisite for receptor resensitization on 
the plasma membrane to return to a functionally active state. In this context, the different ESAs, which 
are characterized by strong, chemical structure variability, may affect the EPOR endocytic machinery 
and may differentially control receptor regulatory mechanisms. DarbEPO is biochemically distinct 
from EPO and has a higher molecular weight and a greater negative charge [38,58]. DarbEPO contains 
five N-linked carbohydrate chains, two more than EPO, and this chemical modification allows 
DarbEPO to carry a maximum of 22 sialic acid residues compared to EPO, which supports a maximum 
of 14 sialic acid residues. These molecular modifications to EPO determined a reduction in EPOR 
binding affinity for hyperglycosylated analogues and an increase in the ligand-receptor dissociation 
constant from the receptor with a consequent loss in the amount of ESA degradation. [59,60]. CERA 
was obtained by the introduction of a large methoxy-polyethyleneglycol polymer chain into the EPO 
molecule via amide bonds between the N-terminal group of alanine and the S-amino groups of  
lysine with a succinimidyl butanoic acid linker [61]. Receptor binding characteristics and the 
pharmacokinetics of CERA differ quite significantly from the first and second generation ESAs [62]. 
CERA has a lower affinity for its receptor and dissociates more quickly from the receptor [63]. It is 
hypothesized that the binding of CERA to its receptor is too brief to allow for internalization of the 
molecule, and this may account for the repeated binding, stimulation and dissociation that leads to 
prolonged activity in vivo and an extended elimination half-life. In addition, binding of CERA to its 
receptor could be too brief to allow for receptor internalization and may account for the rapid recovery 
of receptor functioning after desensitization. 
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To determine whether these ESAs may affect EPOR turnover as a consequence of different receptor 
binding mechanisms, we evaluated the effect of receptor desensitization/resensitization induced by the 
three epoetins on EPOR expression. We demonstrated that EPOR, after desensitization induced by 
EPOα, DarbEPO and CERA, is rapidly downregulated. After EPOα or CERA treatment, the receptor 
resensitized, and this process involved the synthesis of a new pool of receptor protein. Conversely, 
following treatment with DarbEPO, the physiological turnover of EPOR appeared to be impaired. In 
this case, there was no new EPOR synthesis, the levels of receptor protein remained low and the 
receptor was not able to recycle to the plasma membrane in an active functional state.  
Based on these data, we hypothesize that the reversible desensitization of EPOR, other than serving 
to turn-off a biological response, may acts as an “on” switch to sustain long-term signaling and control 
of receptor expression at the nuclear level. Differences in the chemical structure of the epoetins most 
likely affects the endocytic machinery of EPOR and may differentially control EPOR turnover with 
important functional consequences for the receptor. 
Further experiments investigating the intracellular route of EPOR following activation by the 
different ESAs are necessary to specifically identify the molecular mechanisms underlying the 
different effects of ESAs on EPOR regulatory mechanisms.  
Taken together, our results demonstrate the following: 
In HUVECs, the EPOR agonists EPOα, DarbEPO and CERA induced the time- and  
concentration-dependent stimulation of STAT-5 proteins. 
ESAs modulate HUVEC viability through a mechanism likely involving STAT-5 phosphorylation, 
and ESAs also increase angiogenesis.  
These agonists regulated the functional response of EPORs over time, causing time- and 
concentration-dependent receptor desensitization, with similar kinetics for EPOα and DarbEPO and 
more rapid kinetics for CERA. 
The three epoetins displayed significant differences in receptor resensitization. The kinetics of 
receptor resensitization were strictly dependent on the type of agonist, agonist concentration and the 
duration of receptor exposure to the agonist. The rate of EPOR resensitization was greater for CERA 
compared to EPOα or DarbEPO and is slower when the duration of agonist exposure is prolonged. 
These differences could be ascribed to the differential regulation of EPOR turnover. 
These data support the hypothesis that the activation of EPOR by low-dose ESAs for a short period 
of time is an essential pre-requisite for maintaining the receptor in a functional state in endothelial 
cells. These results may represent an important starting point for setting new therapeutic protocols for 
EPO and its derivatives in the treatment of vascular injury.  
Although it may be difficult to translate our data into an in vivo model, the study of EPOR 
regulatory mechanisms in cells is a critical starting point for dissecting the functional responsiveness 
of EPORs during ESA activation for individual optimization of an efficacious therapy. Although the 
availability of long-lasting drugs is clinically useful in terms of cost and number of administrations, it 
should be noted that the choice of different ESAs and the use of high doses of these drugs may affect 
the physiological turnover of the receptor and may cause the onset of drug resistance with consequent 
drug dose increases to obtain similar pharmacological effects.  
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4. Materials and Methods 
4.1. Materials 
Recombinant erythropoietin (EPOα) was kindly supplied by Janssen-Cilag (Milan, Italy). 
Hyperglycosylated recombinant DarbEPO was purchased from Amgen Dompé SpA (Milan, Italy). 
CERA was purchased from Roche Diagnostic, Italy. Human umbilical vein endothelial cells (HUVECs) 
and cell culture medium (EGM®-2 BulletKit®) were purchased from Lonza srl (Milan, Italy). The 
RayBio® Cell-Based STAT-5 (Tyr694) ELISA kit was purchased from RayBiotech Inc. (Norcross, 
GA, USA). The STAT-5 inhibitor N'-((4-Oxo-4H-chromen-3-yl)methylene)nicotinohydrazide was 
purchased from Calbiochem (Merck-Millipore, Nottingham, UK). All other chemicals were supplied 
by standard commercial sources. 
4.2. Cell Lines and Drug Treatments 
HUVECs were seeded onto 1% (wt./vol.) gelatin-coated tissue culture flasks and maintained in 
EGM®-2 BulletKit® medium supplemented with 10% FBS. Cells (2500 cells/cm2) were grown at  
37 °C in a humid atmosphere in the presence of 5% CO2. HUVECs were grown to 80% confluence 
and collected with the specific commercial solution, OneReagentPack™. The cells were used in 
successive experiments until the fourth detaching passage. The cells were treated with different ESA 
doses ranging from 1 IU/mL to 10 IU/mL. The doses of EPOα, DarbEPO and CERA used in the 
experiments were standardized based on the dose-conversion ratio (DCR) between EPOα and other 
ESAs as follows: 1 µg DarbEPO or CERA corresponds biophysically to 200 IU rhEPO peptide [64].  
4.3. STAT-5 Phosphorylation Assay  
To investigate EPOR-mediated STAT-5 phosphorylation, HUVECs were maintained in the 
appropriate serum and growth factor deprivation conditions (SFGD) prior to the assay. To determine 
the optimal experimental conditions for evaluating cell signaling caused by EPOR activation, the 
following three culture conditions were analyzed: (1) cells were starved for 12–24 h before the 
experiment using M199 medium devoid of FBS and growth factors and supplemented with 0.5% 
bovine serum albumin (BSA) and 0.2 mM sodium orthovanadate (OVD) (buffer 1); (2) cells were 
starved for 12 h before the experiment using M199 medium devoid of FBS and growth factors in the 
absence of BSA (buffer 2); and (3) cells were starved for 12 h before the experiment using M199 
medium devoid of FBS and growth factors and supplemented with 0.2 mM OVD 30 min before 
experiments (buffer 3). For all experimental conditions, the effect of EPO (1 IU/mL) treatment for 
different periods of time (5–10 and 30 min) on STAT-5 phosphorylation was evaluated following the 
instructions provided with the kit. Briefly, following EPOR stimulation, HUVECs were fixed to 
preserve any protein modifications, including phosphorylation. After blocking, anti-phospho-STAT-5 
(Tyr694) or anti-STAT-5 (primary antibody) was added to the wells. The wells were washed and  
HRP-conjugated anti-mouse IgG (secondary antibody) was added to the wells for one hour. After 
washing, TMB substrate solution was added to the wells and the color developed in proportion to the 
amount of protein. The stop solution changed the color from blue to yellow, and the intensity of the 
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color was measured at 450 nm. The signals were normalized to the cell number in each well using a 
0.1% crystal violet solution assay, and the data were then plotted.  
In the experimental set, vascular endothelial growth factor (VEGF, 25 ng/mL) and  
granulocyte-macrophage colony-stimulating factor (GM-CSF, 5 ng/mL) were used as  
positive controls. 
4.4. EPO-Mediated STAT-5 Phosphorylation: Concentration and Time Dependence 
After determining the optimal experimental conditions, the concentration- and time-dependent 
activation of STAT-5 phosphorylation induced by the EPOR agonists, EPOα, DarbEPO and CERA, 
were evaluated. After serum starvation for 24 h in buffer 1, the cells were treated for different times  
(1–30 min) with EPOα (1 IU/mL, corresponding to 8.4 ng/mL), DarbEPO (1 IU/mL, corresponding to 
5 ng/mL) or CERA (5 IU/mL, corresponding to 16.7 ng/mL) in buffer 1. In parallel, the same 
experiments were performed in the presence of the STAT-5 inhibitor N'-((4-Oxo-4H-chromen-3-
yl)methylene)nicotinohydrazide (80 µM) [38]. The cells were then processed, and the levels of  
STAT-5 phosphorylation were quantified as described above.  
4.5. Viability Assay 
To evaluate the effects of the ESA derivatives on HUVEC viability, the cells were treated for 72 h 
with EPO (1 IU/mL), DarbEPO (1 IU/mL) or CERA (5 IU/mL) in the absence or presence of 80 µM 
STAT-5 inhibitor. Cell viability was determined by a tetrazolium salt-based assay (Promega CellTiter 
96® AQueous Cell Proliferation Assay), according to the manufacturers’ instructions. The production of 
formazan in the cell culture was measured by absorbance at 490 nm using a microplate reader  
(Victor Wallac 2, Perkin Elmer, CA, USA).  
4.6. In Vitro Angiogenesis Model 
For the in vitro tube formation assay, HUVECs were seeded onto gelatin-coated 6-well plates and 
incubated with assay medium with the addition of drugs (EPOα 1 IU/mL, DarbEPO 1 IU/mL,  
CERA 5 IU/mL, with or without STAT-5 inhibitor). After 24 h, the cells were detached with  
trypsin-EDTA, and 7 × 104 cells per well were seeded in 24-well plates coated with 250 μL 10 mg/mL 
Matrigel (BD Bioscence, Franklin Lakes, NJ, USA)  that was thawed on ice at 4 °C and allowed to 
solidify at 37 °C for 30 min prior to cell seeding. After 20 h, the tube structures were observed with an 
inverted microscope (Hund, Wetzlar, Germany) equipped with a digital camera (Nikon, Sesto 
Fiorentino, Italy). Six fields (magnification 10×) were captured for each sample, performed in 
duplicate. For each image, the total length of the tube network and the number of intact loops were 
quantified with the image analysis software ImageJ (public domain, Image Processing and Analysis in 
Java, National Institutes of Health) using the plug-in AngioJ for the angiogenesis assay. 
4.7. EPOR Desensitization 
To measure desensitization, EPOR-mediated STAT-5 phosphorylation was evaluated following 
exposure of the cells to different EPOα, DarbEPO or CERA concentrations for different periods of 
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time. Specifically, the concentration-dependence desensitization treatments were performed by 
incubating the cells with medium alone (control) or with different concentrations of EPOα, DarbEPO 
or CERA (0.5, 1, 2.5, 5, 10 I U/mL) for 60 min at 37 °C. For the time-dependence experiments, the 
cells were pre-incubated with medium alone (control) or with a selected agonist concentration  
(1 IU/mL for EPOα or DarbEPO and 5 IU/mL for CERA) for different periods of time ranging from 5 
to 120 min. The cell culture medium contained sodium orthovanadate to avoid dephosphorylation of 
the receptor. Following desensitization, the cells were washed three times in buffer 1, and EPOR 
responsiveness was then assessed by evaluating the EPOα- (1 IU/mL for 5 min), DarbEPO- (1 IU/mL 
for 5 min) or CERA-induced (5 IU/mL for 5 min) phosphorylation of STAT-5.  
4.8. EPOR Resensitization Experiments 
HUVECs were treated for 18 or 54 min with buffer 1 alone (control), 1 IU/mL or 3 IU/mL EPOα or 
DarbEPO or 5 IU/mL CERA to induce receptor desensitization. Following desensitization treatment, 
the cells were washed and incubated with medium in the absence of EPOR agonists for 2 to 24 h for 
resensitization. Following this incubation, the recovery of receptor responsiveness was quantified by 
evaluating EPOα- (1 IU/mL for 5 min), DarbEPO- (3 IU/mL for 5 min) or CERA-induced (5 IU/mL 
for 5 min) phosphorylation of STAT-5. In the resensitization experiments, sodium orthovanadate was 
not included in the cell culture medium, because de-phosphorylation processes are required for the 
recovery of receptor responsiveness. 
4.9. EPOR mRNA Expression 
The relative mRNA quantification of EPOR was performed by real-time polymerase chain reaction 
(real-time PCR). HUVECs were treated for 54 min with complete medium (control), EPOα (1 IU/mL), 
DarbEPO (1 IU/mL) or CERA (5 IU/mL). Following treatment with the three epoetins for 54 min, 
aliquots of cells were incubated in medium alone for 24 h to allow for receptor resensitization. Total 
RNA was then isolated using the RNeasy® Mini Kit. Total RNA (1 μg) was reverse transcribed using a 
QuantiTect Transcription Kit in a total volume of 20 μL. The RT-PCR mixture contained a total 
volume of 25 μL consisting of 12.5 μL DyNAmo Flash SYBR Green qPCR Mastermix 
(ThermoScientific), 5 μL cDNA, 3.5 μL H2O and 1 µM of the following primers: β-actin forward  
5'-CGTCTTCCCCTCCATCG-3' and reverse 5'-GCTTTTTTGTCCAGGCACTTCAT-3' and EPOR 
forward 5'-AGCCCAGAGAGCGAGTTTGA-3' and reverse 5'-CCACAGGCAGCCATCATTCT-3'. 
All reactions were performed for 40 cycles using the following temperature profiles: 98 °C for 30 s 
(initial denaturation), 60 °C for 30 s (annealing) and 72 °C for 30 s (extension). β-actin was used as the 
housekeeping gene. The mRNA levels for each sample were normalized against the β-actin mRNA 
levels, and the relative expression was calculated using the Ct value. PCR specificity was determined 
by both melting curve analysis and gel electrophoresis, and the data were analyzed by the standard 
curve method.  




Statistical analysis and graphical presentation were performed with Graph-Pad Prism 4 software 
(Graph-Pad Software Inc, San Diego, CA, USA, 2007). The data were analyzed using one-way 
analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test. A p value < 0.05 
was considered statistically significant. All of the data are presented as the mean ± SEM. 
Acknowledgements 
These studies were supported by an unrestricted grant from Janssen Cilag SpA. 
References 
1. Erslev, A. Humoral regulation of red cell production. Blood 1953, 8, 349–357. 
2. Lai, P.H.; Everett, R.; Wang, F.F.; Arakawa, T.; Goldwasser, E. Structural characterization of 
human erythropoietin. J. Biol. Chem. 1986, 261, 3116–3121. 
3. Bazan, J.F. Structural design and molecular evolution of a cytokine receptor superfamily.  
Proc. Natl. Acad. Sci. USA 1990, 87, 6934–6938. 
4. Lin, C.S.; Lim, S.K.; D’Agati, V.; Costantini, F. Differential effects of an erythropoietin receptor 
gene disruption on primitive and definitive erythropoiesis. Genes Dev. 1996, 10, 154–164. 
5. Anagnostou, A.; Liu, Z.; Steiner, M.; Chin, K.; Lee, E.S.; Kessimian, N.; Noguchi, C.T. 
Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. USA 
1994, 91, 3974–3978. 
6. Morishita, E.; Masuda, S.; Nagao, M.; Yasuda, Y.; Sasaki, R. Erythropoietin receptor is  
expressed in rat hippocampal and cerebral cortical neurons and erythropoietin prevents in vitro  
glutamate-induced neuronal death. Neuroscience 1997, 76, 105–116. 
7. Banerjee, D.; Rodriguez, M.; Nag, M.; Adamson, J.W. Exposure of endothelial cells to 
recombinant human erythropoietin induces nitric oxide synthase activity. Kidney Int. 2000, 57, 
1895–1904. 
8. Stasko, J.; Drouet, L.; Soria, C.; Mazoyer, E.; Caen, J.; Kubisz, P. Erythropoietin and granulocyte 
colony-stimulating factor increase plasminogen activator inhibitor-1 release in HUVEC culture. 
Thromb. Res. 2002, 105, 161–164. 
9. Congote, L.F.; Sadvakassova, G.; Dobocan, M.C.; Difalco, M.R.; Li, Q. Erythropoietin-dependent 
endothelial proteins: Potential use against erythropoietin resistance. Cytokine 2010, 51, 113–118. 
10. Noguchi, C.T.; Wang, L.; Rogers, H.M.; Teng, R.; Jia, Y. Survival and proliferative roles of 
erythropoietin beyond the erythroid lineage. Expert Rev. Mol. Med. 2008, 10, e36. 
11. Heeschen, C.; Aicher, A.; Lehmann, R.; Fichtlscherer, S.; Vasa, M.; Urbich, C.;  
Mildner-Rihm, C.; Martin, H.; Zeiher, A.M.; Dimmeler, S. Erythropoietin is a potent physiologic 
stimulus for endothelial progenitor cell mobilization. Blood 2003, 102, 1340–1346. 
12. Santhanam, A.V.; d’Uscio, L.V.; Peterson, T.E.; Katusic, Z.S. Activation of endothelial nitric 
oxide synthase is critical for erythropoietin-induced mobilization of progenitor cells. Peptides 
2008, 29, 1451–1455. 
Int. J. Mol. Sci. 2013, 14 2278 
 
 
13. Westenbrink, B.D.; Lipsic, E.; van der Meer, P.; van der Harst, P.; Oeseburg, H.;  
Du Marchie Sarvaas, G.J.; Koster, J.; Voors, A.A.; van Veldhuisen, D.J.; van Gilst, W.H.; et al. 
Erythropoietin improves cardiac function through endothelial progenitor cell and vascular 
endothelial growth factor mediated neovascularization. Eur. Heart. J. 2007, 28, 2018–2027. 
14. Brines, M.; Cerami, A. Discovering erythropoietin’s extra-hematopoietic functions: Biology and 
clinical promise. Kidney Int. 2006, 70, 246–250. 
15. Haller, H.; Christel, C.; Dannenberg, L.; Thiele, P.; Lindschau, C.; Luft, F.C. Signal transduction 
of erythropoietin in endothelial cells. Kidney Int. 1996, 50, 481–488. 
16. Yang, J.; Xiao, Z.; Li, T.; Gu, X.; Fan, B. Erythropoietin promotes the growth of pituitary 
adenomas by enhancing angiogenesis. Int. J. Oncol. 2012, 40, 1230–1237. 
17. Kawachi, K.; Iso, Y.; Sato, T.; Wakabayashi, K.; Kobayashi, Y.; Takeyama, Y.; Suzuki, H. 
Effects of erythropoietin on angiogenesis after myocardial infarction in porcine. Heart Vessels 
2012, 27, 79–88.  
18. Carlini, R.G.; Reyes, A.A.; Rothstein, M. Recombinant human erythropoietin stimulates 
angiogenesis in vitro. Kidney Int. 1995, 47, 740–745.  
19. Ahn, S.; Min, S.K.; Min, S.I.; Suh, J.H.; Kim, S.J.; Ha, J. Early sustained injections of 
erythropoietin improve angiogenesis and restoration of perfusion in the ischemic mouse hindlimb. 
J. Korean Med. Sci. 2012, 27, 1073–1078.  
20. Ribatti, D.; Presta, M.; Vacca, A.; Ria, R.; Giuliani, R.; Dell’Era, P.; Nico, B.; Roncali, L.; 
Dammacco, F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial 
cells and stimulates neovascularization in vivo. Blood 1999, 93, 2627–2636.  
21. Constantinescu, S.N.; Ghaffari, S.; Lodish, H.F. The erythropoietin receptor: Structure, activation 
and intracellular signal transduction. Trends Endocrinol. Metab. 1999, 10, 18–23. 
22. Fliser, D.; Bahlmann, F.H. Erythropoietin and the endothelium—A promising link? Eur. J.  
Clin. Invest. 2008, 38, 457–461. 
23. Marzo, F.; Lavorgna, A.; Coluzzi, G.; Santucci, E.; Tarantino, F.; Rio, T.; Conti, E.; Autore, C.; 
Agati, L.; Andreotti, F. Erythropoietin in heart and vessels: Focus on transcription and signaling 
pathways. J. Thromb. Thrombolysis 2008, 26, 183–187.  
24. Janmaat, M.L.; Heerkens, J.L.; de Bruin, A.M.; Klous, A.; de Waard, V.; de Vries, C.J. 
Erythropoietin accelerates smooth muscle cell-rich vascular lesion formation in mice through 
endothelial cell activation involving enhanced PDGF-BB release. Blood 2010, 115, 1453–1460. 
25. Fusté, B.; Serradell, M.; Escolar, G.; Cases, A.; Mazzara, R.; Castillo, R.; Ordinas, A.;  
Díaz-Ricart, M. Erythropoietin triggers a signaling pathway in endothelial cells and increases the 
thrombogenicity of their extracellular matrices in vitro. Thromb Haemostasis 2002, 88, 678–685.  
26. Su, K.H.; Shyue, S.K.; Kou, Y.R.; Ching, L.C.; Chiang, A.N.; Yu, Y.B.; Chen, C.Y.; Pan, C.C.; 
Lee, T.S. β Common receptor integrates the erythropoietin signaling in activation of endothelial 
nitric oxide synthase. J. Cell Physiol. 2011, 226, 3330–3339. 
27. Locatelli, F.; Olivares, J.; Walker, R.; Wilkie, M.; Jenkins, B.; Dewey, C.; Gray, S.J. Novel 
erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency.  
Kidney Int. 2001, 60, 741–747. 
28. Elliott, S.; Pham, E.; Macdougall, I.C. Erythropoietins: A common mechanism of action.  
Exp. Hematol. 2008, 36, 1573–1584. 
Int. J. Mol. Sci. 2013, 14 2279 
 
 
29. Klingmuller, U.; Lorenz, U.; Cantley, L.C.; Neel, B.C.; Lodish, H.C. Specific recruitment of  
SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of 
proliferative signals. Cell 1995, 80, 729–738. 
30. Mufson, R.A.; Gesner, T.G. Binding and internalization of recombinant human erythropoietin in 
murine erythroid precursor cells. Blood 1987, 69, 1485–1490. 
31. Levin, I.; Cohen, J.; Supino-Rosin, L.; Yoshimura, A., Watowich, S.S.; Neumann, D. 
Identification of a cytoplasmic motif in the erythropoietin receptor required for receptor 
internalization. FEBS Lett. 1998, 427, 164–170. 
32. Zuo, G.; Guan, T.; Chen, D.; Li, C.; Jiang, R.; Luo, C.; Hu, X.; Wang, Y.; Wang, J. Total 
saponins of Panax ginseng induces K562 cell differentiation by promoting internalization of the 
erythropoietin receptor. Am. J. Chin. Med. 2009, 37, 747–757. 
33. Sulahian, R.; Cleaver, O.; Huang, L.J. Ligand-induced EpoR internalization is mediated by JAK2 
and p85 and is impaired by mutations responsible for primary familial and congenital 
polycythemia. Blood 2009, 113, 5287–5297. 
34. Flint-Ashtamker, G.; Eisen-Lev, R.; Cohen, J.; Huang, L.J.; Neumann, D. Amino acid residues 
268-276 of the erythropoietin receptor contain an endocytosis motif and are required for 
erythropoietin-mediated proliferation. FEBS Lett. 2002, 518, 189–194. 
35. Walrafen, P.; Verdier, F.; Kadri, Z.; Chrétien, S.; Lacombe, C.; Mayeux, P. Both proteasomes and 
lysosomes degrade the activated erythropoietin receptor. Blood 2005, 105, 600–608. 
36. Verdier, F.; Walrafen, P.; Hubert, N.; Chretien, S.; Gisselbrecht, S.; Lacombe, C.; Mayeux, P. 
Proteasomes regulate the duration of erythropoietin receptor activation by controlling  
downregulation of cell surface receptors. J. Biol. Chem. 2000, 275, 18375–18381. 
37. Yen, C.H.; Yang, Y.C.; Ruscetti, S.K.; Kirken, R.A.; Dai, R.M.; Li, C.C. Involvement of the 
ubiquitin-proteasome pathway in the degradation of nontyrosine kinase-type cytokine receptors of 
IL-9, IL-2 and erythropoietin. J. Immunol. 2000, 165, 6372–6380. 
38. Müller, J.; Sperl, B.; Reindl, W.; Kiessling, A.; Berg, T. Discovery of chromone-based inhibitors 
of the transcription factor STAT5. ChemBioChem 2008, 9, 723–727.  
39. Małyszko, J.S.; Małyszko, J.; Pawlak, K.; Pawlak, K.; Buczko, W.; Myśliwiec, M. Importance of 
serotonergic mechanisms in the thrombotic complications in hemodialyzed patients treated with 
erythropoietin. Nephron 2000, 84, 305–311. 
40. Borawski, J.; Mysliwiec, M. Effects of recombinant erythropoietin therapy on circulating 
endothelial markers in hemodialysis patients. Clin. Appl. Thromb. Hemostasis 2002, 8, 77–84. 
41. Staško, J.; Kubisz, P. Increased soluble thrombomodulin in hemodialysis patients with long-term 
erythropoietin treatment: What does it reflect? Clin. Appl. Thromb. Hemostasis 2003, 9, 349–352. 
42. Taylor, J.E.; Belch, J.J.F.; McLaren, M.; Henderson, J.S.; Stewart, W.K. Effect of erythropoietin 
therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients. Kidney 
Int. 1993, 44, 182–190. 
43. Pawlak, K.; Pawlak, D.; Mysliwiec, M. Long-term erythropoietin therapy does not affect 
endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients. 
Thromb. Res. 2007, 120, 797–803. 
Int. J. Mol. Sci. 2013, 14 2280 
 
 
44. Bahlmann, F.H.; Song, R.; Boehm, S.M.; Mengel, M.; von Wasielewski, R.; Lindschau, C.; 
Kirsch, T.; de Groot, K.; Laudeley, R.; Niemczyk, E.; et al. Low-dose therapy with the  
long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and 
attenuates progressive organ failure. Circulation 2004, 110, 1006–1012. 
45. Kanellakis, P.; Pomilio, G.; Agrotis, A.; Gao, X.; Du, X.J.; Curtis, D.; Bobik, A.  
Darbepoetin-mediated cardioprotection after myocardial infarction involves multiple mechanisms 
independent of erythropoietin receptor-common beta-chain heteroreceptor. Br. J. Pharmacol. 
2010, 160, 2085–2096. 
46. Baker, J.E.; Kozik, D.; Hsu, A.K.; Fu, X.; Tweddell, J.S. Gross G.J. Darbepoetin alfa protects the 
rat heart against infarction: Dose-response, phase of action and mechanisms. J. Cardiovasc. 
Pharmacol. 2007, 49, 337–345. 
47. Opie, L.H. Erythropoietin as a cardioprotective agent: Down, but not out. Heart 2011, 97,  
1537–1539. 
48. Minamino, T.; Toba, K.; Higo, S.; Nakatani, D.; Hikoso, S.; Umegaki, M.; Yamamoto, K.;  
Sawa, Y.; Aizawa, Y.; Komuro, I. Design and rationale of low-dose erythropoietin in patients 
with ST-segment elevation myocardial infarction (EPO-AMI-II study): A randomized controlled 
clinical trial. Cardiovasc. Drugs Ther. 2012, 26, 409–416. 
49. Inrig, J.K.; Bryskin, S.K.; Patel, U.D.; Arcasoy, M.; Szczech, L.A. Association between high-dose 
erythropoiesis-stimulating agents, inflammatory biomarkers and soluble erythropoietin receptors. 
BMC Nephrol. 2011, 12, 67–77. 
50. Sawyer, S.T.; Penta, K. Association of JAK2 and STAT5 with erythropoietin receptors. Role of 
receptor phosphorylation in erythropoietin signal transduction. J. Biol. Chem. 1996, 271,  
32430–32437. 
51. Ji, Y.Q.; Zhang, Y.Q.; Li, M.Q.; Du, M.R.; Wei, W.W.; Li, D.J. EPO improves the proliferation 
and inhibits apoptosis of trophoblast and decidual stromal cells through activating STAT-5 and 
inactivating p38 signal in human early pregnancy. Int. J. Clin. Exp. Pathol. 2011, 4, 765–774.  
52. Mezentsev, A.; Merks, R.M.; O’Riordan, E.; Chen, J.; Mendelev, N.; Goligorsky, M.S.;  
Brodsky, S.V. Endothelial microparticles affect angiogenesis in vitro: Role of oxidative stress.  
Am. J. Physiol. Heart Circ. Physiol. 2005, 289, H1106–H1114. 
53. Aranda, E.; Owen, G.I. A semi-quantitative assay to screen for angiogenic compounds and 
compounds with angiogenic potential using the EA.hy926 endothelial cell line. Biol. Res. 2009, 
42, 377–389. 
54. El-Komy, M.H.; Schmidt, R.L.; Widness, J.A.; Veng-Pedersen, P. Differential pharmacokinetic 
analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous 
erythropoietin receptor activator in sheep. Biopharm. Drug Dispos. 2011, 32, 276–288. 
55. Bulut, G.B.; Sulahian, R.; Ma, Y.; Chi, N.W.; Huang, L.J. Ubiquitination regulates the 
internalization, endolysosomal sorting and signaling of the erythropoietin receptor. J. Biol. Chem. 
2011, 286, 6449–6457.  
56. Suzuki, N.; Ohneda, O.; Takahashi, S.; Higuchi, M.; Mukai, H.Y.; Nakahata, T.; Imagawa, S.; 
Yamamoto, M. Erythroid-specific expression of the erythropoietin receptor rescued its null 
mutant mice from lethality. Blood 2002, 100, 2279–2288. 
Int. J. Mol. Sci. 2013, 14 2281 
 
 
57. Meyer, L.; Deau, B.; Forejtníková, H.; Duménil, D.; Margottin-Goguet, F.; Lacombe, C.;  
Mayeux, P.; Verdier, F. beta-Trcp mediates ubiquitination and degradation of the erythropoietin 
receptor and controls cell proliferation. Blood 2007, 109, 5215–5222.  
58. Macdougall, I.C. Novel erythropoiesis-stimulating agents: A new era in anemia management. 
Clin. J. Am. Soc. Nephrol. 2008, 3, 200–207.  
59. Elliott, S.; Egrie, J.; Browne, J.; Lorenzini, T.; Busse, L.; Rogers, N.; Ponting, I. Control of 
rHuEPO biological activity: The role of carbohydrate. Exp. Hematol. 2004, 32, 1146–1155. 
60. Gross, A.W.; Lodish, H.F. Cellular trafficking and degradation of erythropoietin and novel 
erythropoiesis stimulating protein (NESP). J. Biol. Chem. 2006, 281, 2024–2032.  
61. Macdougall, I.C. CERA (Continuous erythropoietin receptor activator): A new  
erythropoiesis-stimulating agent for the treatment of anemia. Curr. Hematol. Rep. 2005, 4,  
436–440. 
62. Macdougall, I.C.; Robson, R.; Opatrna, S.; Liogier, X.; Pannier, A.; Jordan, P.; Dougherty, F.C.; 
Reigner, B. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous 
continuous erythropoietin receptor activator (CERA) in patients with chronic kidney disease.  
Clin. J. Am. Soc. Nephrol. 2006, 1, 1211–1215. 
63. Jarsch, M.; Brandt, M.; Lanzendörfer, M.; Haselbeck, A. Comparative erythropoietin receptor 
binding kinetics of CERA and epoetin-beta determined by surface plasmon resonance and 
competition binding assay. Pharmacology 2008, 81, 63–69. 
64. Egrie, J.C.; Browne, J.K. Development and characterization of novel erythropoiesis stimulating 
protein (NESP). Nephrol. Dial. Transplant. 2001, 16, 3–13. 
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
